$RVPH News

RVPH: First Quarter 2026 Results

Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Q1 EPS $(0.46) Beats $(0.62) Estimate

Reviva Pharmaceuticals Holdings To Be Delisted From Nasdaq, Shares To Begin Trading On OTCQB On May 14, 2026

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans

RVPH: Shareholder Letter Introduces New IP

Reviva Announces Letter to Shareholders

Reviva Pharmaceuticals Holdings Says Aims To Extend Brilaroxazine Patent Life And Exclusivity Potentially Through 2046; To Initiate Trial Activities In Q2 2026, Begin Enrollment In Q3 2026, For RECOVER-2; Preparing To Seek FDA Alignment On New Form Of Brilaroxazine For NDA

Maxim Group Downgrades Reviva Pharmaceuticals to Hold

RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2

Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Reviva Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Q4 EPS $(0.57) Misses $(0.10) Estimate

Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

What's Behind The Drop In Reviva Pharmaceuticals Stock?